Broadcasting News

Son Ye-jin, Ji Chang-wook, and Nana’s “Scandal” Ranks 3rd Among Netflix’s Non-English Shows

Recorded 2.8 million views Top 10 in 18 Countries

Gim Ga Yeong
2026-09-30 09:59:08
[Edaily Starin Gim Ga Yeong Reporter] The Netflix series “Scandal” ranked third among the top 10 global non-English shows in its second week of release.
According to Netflix’s official site, Tudum, on the 30th, “Scandal” recorded 2.8 million views (viewing time divided by the show’s total running time) in its second week of release, ranking third among global non-English shows. Total viewing time reached 21.9 million. The series made the Top 10 in a total of 18 countries, including South Korea, Hong Kong, Bangladesh, El Salvador, Indonesia, Japan, Kuwait, Malaysia, the Philippines, and Qatar.
No other Korean productions made the list.
“Scandal” is a series that tells the story of “Lady Jo”—a woman with exceptional talent who feels confined by her role as a woman in the Joseon Dynasty—and “Jo Won,” the Joseon Dynasty’s greatest womanizer, as they engage in a daring and dangerous love wager, as well as the story of “Hee-yeon,” a woman entangled in that wager. The series garnered significant attention thanks to its star-studded cast, including Son Ye-jin, Ji Chang-wook, and Nana.

Economy

Corporation

IT·Science

Economy

Kaia Chairman: "It’s the 'Golden Time' for K-Blockchain… It Should Be Operated Using a Won-Pegged Stablecoin"

A proposal has been put forward to establish a Korea-led blockchain infrastructure ahead of the institutionalization of won-pegged stablecoins and security token offerings (STOs). The vision calls for…
2026-11-20 14:50:02

Corporation

curacle co., ltd. Files for U.S. Phase 2b Clinical Trial of CU06, an Oral Treatment for Diabetic Macular Edema

curacle co., ltd.(365270)is moving forward with a U.S. Phase 2b clinical trial to develop an oral treatment for diabetic macular edema (DME). The trial will re-evaluate the treatment’s efficacy in pat…
2026-11-20 13:02:02

IT·Science

Aimed Bio Inc.’s ADC Technology Export Shows 60% Response Rate in Phase 1 Clinical Trial… Moving Forward with U.S. Approval Trials

#Aimed Bio Inc.’s antibody-drug conjugate (ADC) “BHV-1530 (AMB302),” which was licensed to U.S.-based Biohaven, has demonstrated initial anticancer efficacy in a Phase 1 clinical trial. Biohaven plans…
2026-11-20 13:07:02